CytomX Therapeutics Inc. reported cash, cash equivalents and investments of $143.6 million at the end of the third quarter of 2025, with an expected cash runway through the second quarter of 2027. Total operating expenses for the third quarter of 2025 were $21.7 million, down from $29.3 million in the same period of 2024. Research and development expenses were $15.3 million, a decrease of $6.1 million compared to the prior year, primarily due to reduced spending on the CX-904 program, restructuring, and lower CX-2051 manufacturing costs, partially offset by higher CX-2051 clinical expenses. General and administrative expenses were $6.4 million, down $1.5 million year-over-year, mainly due to lower personnel, patent, and legal costs. Key business developments included continued progress in the CX-2051 Phase 1 trial, with a data update expected in the first quarter of 2026, and ongoing research collaborations focused on bispecific immunotherapies.